The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.本發明提供治療罹患BRAF V600突變或BRAF融合突變相關之疾病或病狀或處於其風險中之個體,但不活化含有野生型BRAF之細胞中的MAPK路徑或不誘導含有野生型BRAF之細胞表現MAPK路徑基因的方法。